Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua
Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua
IPO

Tigermed roars in its Hong Kong stock trading debut, as Asia’s largest health care IPO of 2020 draws traders to its clinical trials

  • Clinical trial and research firm’s secondary listing was the biggest in Asia this year
  • Will use funds to expand overseas

Topic |   IPO
Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua
Vaccines for inactivating the coronavirus being tested at China National Pharmaceutical Group (Sinopharm) in Beijing on April 11, 2020. Photo: Xinhua
READ FULL ARTICLE